CANADA LIFE ASSURANCE Co Cuts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

CANADA LIFE ASSURANCE Co lessened its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 84.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,649 shares of the biotechnology company's stock after selling 36,699 shares during the quarter. CANADA LIFE ASSURANCE Co's holdings in REGENXBIO were worth $51,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after buying an additional 1,659,206 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after acquiring an additional 296,700 shares in the last quarter. Barclays PLC increased its stake in shares of REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock valued at $1,217,000 after acquiring an additional 67,948 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 2,510 shares during the period. Finally, Geode Capital Management LLC boosted its stake in REGENXBIO by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock worth $8,460,000 after acquiring an additional 5,574 shares in the last quarter. Institutional investors own 88.08% of the company's stock.

REGENXBIO Trading Down 2.7 %

NASDAQ RGNX traded down $0.26 during trading hours on Tuesday, hitting $9.50. 81,548 shares of the company's stock traded hands, compared to its average volume of 821,546. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $17.35. The firm has a market capitalization of $476.11 million, a P/E ratio of -1.89 and a beta of 1.11. The business's fifty day moving average price is $7.22 and its two-hundred day moving average price is $8.06.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. On average, sell-side analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on RGNX shares. Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target on the stock. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Leerink Partners set a $24.00 price objective on REGENXBIO in a research note on Tuesday, March 18th. Chardan Capital reiterated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 20th. Finally, Morgan Stanley upped their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.